×
About 7,608 results

ALLMedicine™ Angioedema Center

Research & Reviews  3,293 results

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a ran...
https://doi.org/10.1016/j.jaci.2020.10.015
The Journal of Allergy and Clinical Immunology; Zuraw B, Lumry WR et. al.

Oct 25th, 2020 - Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks. To determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a...

Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant...
https://doi.org/10.1002/jcph.1768
Journal of Clinical Pharmacology References; Wang Y, Jomphe C et. al.

Oct 22nd, 2020 - Elevated bradykinin levels are responsible for the development of clinical symptoms in patients with hereditary angioedema (HAE). Icatibant is a bradykinin type 2 receptor antagonist indicated for the acute treatment of HAE attacks. A population m...

Clinical features of genetically characterized types of hereditary angioedema with norm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559394
Orphanet Journal of Rare Diseases; Bork K, Machnig T et. al.

Oct 16th, 2020 - Hereditary angioedema (HAE) with normal C1 inhibitor (C1-INH) (HAEnCI) is associated with skin swellings, abdominal attacks, and the risk of asphyxia due to upper airway obstruction. Several different gene mutations linked to the HAE phenotype hav...

Angioedema in African Americans Patients Hospitalized for COVID-19.
https://doi.org/10.1164/rccm.202006-2223LE
American Journal of Respiratory and Critical Care Medicine; Batarseh E, Kersten BP et. al.

Oct 14th, 2020 - Angioedema in African Americans Patients Hospitalized for COVID-19.|2020|Batarseh E,Kersten BP,Pinelo AC,Nadler JN,Schwartz SA,|

Cutaneous Manifestations in Adult Patients with COVID-19 and Dermatologic Conditions Re...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549735
Current Allergy and Asthma Reports; Mawhirt SL, Frankel D et. al.

Oct 13th, 2020 - COVID-19 (coronavirus viral disease 2019), due to the novel SARS-CoV-2, may present with different types of cutaneous manifestations of varying pathophysiology. During the ongoing pandemic, publications reporting dermatologic findings in COVID-19 ...

see more →

Guidelines  17 results

The international WAO/EAACI guideline for the management of hereditary angioedema-The 2...
https://doi.org/10.1111/all.13384
Allergy Maurer M, Magerl M et. al.

Jan 10th, 2018 - Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. I...

BSACI guideline for the management of chronic urticaria and angioedema.
https://doi.org/10.1111/cea.12494
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology; Powell RJ, Leech SC et. al.

Feb 25th, 2015 - This guidance for the management of patients with chronic urticaria and angioedema has been prepared by the Standards of Care Committee of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well ...

The diagnosis and management of acute and chronic urticaria: 2014 update
https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Urticaria-2014.pdf
Bernstein, J.

Apr 30th, 2014 - Theworkgroup was formed by the JTFPP to develop a practiceparameter to address the diagnosis and treatment of urticaria withor without angioedema. The chair, Jonathan Bernstein, MD,invited workgroup members to participate in the parameterdevelopme.

A consensus parameter for the evaluation and management of angioedema in the emergency ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100605
Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine; Moellman JJ, Bernstein JA et. al.

Apr 15th, 2014 - Despite its relatively common occurrence and life-threatening potential, the management of angioedema in the emergency department (ED) is lacking in terms of a structured approach. It is paramount to distinguish the different etiologies of angioed...

A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, an...
https://doi.org/10.1016/j.jaci.2013.03.034
The Journal of Allergy and Clinical Immunology; Zuraw BL, Bernstein JA et. al.

Jun 3rd, 2013 - These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council ...

see more →

Drugs  403 results see all →

Clinicaltrials.gov  3,753 results

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a ran...
https://doi.org/10.1016/j.jaci.2020.10.015
The Journal of Allergy and Clinical Immunology; Zuraw B, Lumry WR et. al.

Oct 25th, 2020 - Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks. To determine the efficacy, safety, and tolerability of berotralstat in patients with HAE over a...

Population Pharmacokinetics and Exposure-Response Analyses to Guide Dosing of Icatibant...
https://doi.org/10.1002/jcph.1768
Journal of Clinical Pharmacology References; Wang Y, Jomphe C et. al.

Oct 22nd, 2020 - Elevated bradykinin levels are responsible for the development of clinical symptoms in patients with hereditary angioedema (HAE). Icatibant is a bradykinin type 2 receptor antagonist indicated for the acute treatment of HAE attacks. A population m...

Clinical features of genetically characterized types of hereditary angioedema with norm...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559394
Orphanet Journal of Rare Diseases; Bork K, Machnig T et. al.

Oct 16th, 2020 - Hereditary angioedema (HAE) with normal C1 inhibitor (C1-INH) (HAEnCI) is associated with skin swellings, abdominal attacks, and the risk of asphyxia due to upper airway obstruction. Several different gene mutations linked to the HAE phenotype hav...

Promethazine hydrochloride - promethazine hydrochloride tablet-Bryant Ranch Prepack
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f925d13-3796-40ed-ac51-2d2602b745da

Oct 15th, 2020 - Promethazine Hydrochloride Tablets are useful for: Perennial and seasonal allergic rhinitis.           Vasomotor rhinitis.      Allergic conjunctivitis due to inhalant allergens and foods.    Mild, uncomplicated allergic skin manifestations of urt...

Angioedema in African Americans Patients Hospitalized for COVID-19.
https://doi.org/10.1164/rccm.202006-2223LE
American Journal of Respiratory and Critical Care Medicine; Batarseh E, Kersten BP et. al.

Oct 14th, 2020 - Angioedema in African Americans Patients Hospitalized for COVID-19.|2020|Batarseh E,Kersten BP,Pinelo AC,Nadler JN,Schwartz SA,|

see more →

News  133 results

Recurrent Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema Refractory to Fresh Frozen Plasma
https://www.mdedge.com/fedprac/article/213630/hospital-medicine/recurrent-angiotensin-converting-enzyme-inhibitor-induced/page/0/1?channel=327

Dec 5th, 2019 - Discussion The standard therapy for ACEI-inducedangioedema continues to be airway management and discontinuation of medication. However, life-threatening progression of symptoms have led to the use of off-label therapies, including FFP and bradyki.

HAE Attacks Cut With Lanadelumab
https://www.medpagetoday.com/rheumatology/generalrheumatology/76622

Nov 30th, 2018 - Action Points Patients with type I or type II hereditary angioedema (HAE) suffer from regular, unpredictable and life-disrupting attacks, and patients are in need of better drugs to control this lifelong disabling condition. Patients whose HAE is ...

Trial Data Back Lanadelumab for HAE Prevention
https://www.medpagetoday.com/rheumatology/generalrheumatology/76542

Nov 27th, 2018 - Prophylactic treatment with lanadelumab (Takhzyro) prevented hereditary angioedema attacks and led to a clinically-meaningful impact on quality of life, according to the pivotal HELP trial that led to recent FDA approval. The monoclonal antibody c...

FDA Approves 6th Drug for HAE
https://www.medpagetoday.com/rheumatology/generalrheumatology/74729

Aug 24th, 2018 - WASHINGTON -- A monoclonal antibody drug for hereditary angioedema (HAE) won FDA approval late Thursday, making it the sixth agent to reach the U.S. market for the rare genetic disorder. Lanadelumab (Takhzyro), made by Shire, was approved for prev...

FDA approves new treatment for rare hereditary disease
https://www.fda.gov/Drugs/DrugSafety/ucm618261.htm

The U.S. Food and Drug Administration today approved Takhzyro (lanadelumab), the first monoclonal antibody approved in the U.S. to treat patients 12 years and older with types I and II hereditary angioedema (HAE).

see more →

Patient Education  9 results see all →